Goldman Sachs’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-209,298
| Closed | -$333K | – | 5016 |
|
|
2024
Q1 | $333K | Buy |
209,298
+98,616
| +89% | +$157K | ﹤0.01% | 4151 |
|
|
2023
Q4 | $95.1K | Sell |
110,682
-162,679
| -60% | -$140K | ﹤0.01% | 4469 |
|
|
2023
Q3 | $292K | Buy |
273,361
+36,625
| +15% | +$39.2K | ﹤0.01% | 4116 |
|
|
2023
Q2 | $613K | Buy |
236,736
+45,933
| +24% | +$119K | ﹤0.01% | 3870 |
|
|
2023
Q1 | $778K | Sell |
190,803
-188,855
| -50% | -$771K | ﹤0.01% | 3832 |
|
|
2022
Q4 | $1.91M | Buy |
379,658
+46,019
| +14% | +$231K | ﹤0.01% | 3315 |
|
|
2022
Q3 | $4.36M | Buy |
333,639
+161,433
| +94% | +$2.11M | ﹤0.01% | 2738 |
|
|
2022
Q2 | $2.21M | Buy |
172,206
+8,288
| +5% | +$106K | ﹤0.01% | 3357 |
|
|
2022
Q1 | $2.5M | Sell |
163,918
-42,896
| -21% | -$654K | ﹤0.01% | 3397 |
|
|
2021
Q4 | $3.66M | Sell |
206,814
-44,671
| -18% | -$791K | ﹤0.01% | 3057 |
|
|
2021
Q3 | $5.29M | Buy |
251,485
+193,662
| +335% | +$4.07M | ﹤0.01% | 2751 |
|
|
2021
Q2 | $1.14M | Buy |
57,823
+6,442
| +13% | +$127K | ﹤0.01% | 3926 |
|
|
2021
Q1 | $1.49M | Buy |
51,381
+3,356
| +7% | +$97.6K | ﹤0.01% | 3620 |
|
|
2020
Q4 | $1.45M | Sell |
48,025
-5,097
| -10% | -$154K | ﹤0.01% | 3252 |
|
|
2020
Q3 | $845K | Sell |
53,122
-7,274
| -12% | -$116K | ﹤0.01% | 3401 |
|
|
2020
Q2 | $1.19M | Buy |
60,396
+15,863
| +36% | +$313K | ﹤0.01% | 3130 |
|
|
2020
Q1 | $549K | Sell |
44,533
-41,986
| -49% | -$518K | ﹤0.01% | 3447 |
|
|
2019
Q4 | $1.6M | Buy |
86,519
+32,007
| +59% | +$592K | ﹤0.01% | 3055 |
|
|
2019
Q3 | $755K | Sell |
54,512
-1,691
| -3% | -$23.4K | ﹤0.01% | 3395 |
|
|
2019
Q2 | $823K | Buy |
+56,203
| New | +$823K | ﹤0.01% | 3292 |
|